Form 8-K
8-K — TELEFLEX INC
Accession: 0000096943-26-000101
Filed: 2026-09-09
Period: 2026-09-08
CIK: 0000096943
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — tfx-20260908.htm (Primary)
EX-99.1 (ex991to9-8x2026redirectore.htm)
GRAPHIC (image.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: tfx-20260908.htm · Sequence: 1
tfx-20260908
0000096943false00000969432026-09-082026-09-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported) September 8, 2026
TELEFLEX INCORPORATED
(Exact name of Registrant as Specified in Its Charter)
Delaware 1-5353 23-1147939
(State or Other Jurisdiction
of Incorporation or Organization)
(Commission File Number)
(IRS Employer
Identification No.)
550 E. Swedesford Rd., Suite 400 Wayne, PA 19087
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code (610) 225-6800
Not applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $1 per share TFX New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 8, 2026, the Board of Directors (the “Board”) of Teleflex Incorporated (the “Company”), upon the recommendation of the Nominating and Governance Committee of the Board, approved an increase in the size of the Board from eight to nine directors and elected Sean M. Salmon to the Board to fill the vacancy created by the increase. In connection with his election to the Board, Mr. Salmon was also appointed to the Growth and Operating Committee of the Board.
Mr. Salmon, age 61, currently provides business and strategic consulting and advisory services through his consulting firm, Zamboni Holdings, LLC, which he founded in December 2025. Prior to that, Mr. Salmon had a 21-year career with Medtronic plc, a global healthcare technology company. During his tenure with Medtronic, Mr. Salmon held various executive and senior management positions, including Executive Vice President and President, Cardiovascular from January 2021 to September 2025; Executive Vice President and President, Cardiovascular and Diabetes from December 2020 to May 2022; Executive Vice President and President, Diabetes from October 2019 to December 2020; President, Coronary and Structural Heart Business Units from July 2014 to October 2019; President, Coronary and Renal Denervation Business Units from July 2011 to July 2014; and other senior management level positions from November 2004 to July 2011. Prior to joining Medtronic, Mr. Salmon held positions at C.R. Bard, Inc. (now part of Becton Dickinson and Company) and Johnson & Johnson. Mr. Salmon is currently a director of Adagio Medical Holdings, Inc.
In connection with his service on the Board, Mr. Salmon will receive compensation consistent with the compensation currently provided to all Company non-employee directors, as described on pages 15 to 17 of the Company’s proxy statement for its 2026 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 13, 2026.
There are no arrangements or understandings between Mr. Salmon, on the one hand, and the Company or any other persons, on the other hand, pursuant to which Mr. Salmon was selected as a director. There are no related party transactions between the Company and Mr. Salmon (or any of his immediate family members) requiring disclosure under Item 404(a) of Regulation S-K.
Item 7.01. Regulation FD Disclosure.
On September 8, 2026, the Company issued a press release announcing Mr. Salmon's appointment to the Board. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release, dated September 8, 2026
104 The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 8, 2026
TELEFLEX INCORPORATED
By: /s/ Daniel V. Logue
Name: Daniel V. Logue
Title: Corporate Vice President, General
Counsel & Secretary
EX-99.1
EX-99.1
Filename: ex991to9-8x2026redirectore.htm · Sequence: 2
Document
Exhibit 99.1
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
Wayne, Pa., September 8, 2026 - Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026.
Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE: MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portfolio, a global business with fiscal 2025 revenue of approximately $12.5 billion for which Mr. Salmon was instrumental in developing the growth strategy. He previously held leadership roles across Medtronic’s Diabetes, Coronary and Structural Heart, and Coronary and Renal Denervation businesses. Mr. Salmon currently serves as an independent director of Adagio Medical Holdings, Inc. (Nasdaq: ADGM).
“We are pleased to welcome Sean to the Teleflex Board,” said Andrew A. Krakauer, Chairman of the Teleflex Board of Directors. “Sean is an industry veteran and proven operator with a strong record of driving growth and profitability across large, complex medical technology businesses. His deep expertise in capital allocation, portfolio strategy and operational execution will complement the existing capabilities of the Board and be particularly valuable as Teleflex advances its strategic priorities. We look forward to benefiting from his perspective as we continue to drive durable performance and value for shareholders.”
Mr. Salmon’s appointment highlights the Board’s continued focus on strong governance and ongoing refreshment in support of the Company’s strategic priorities and value creation. Following his appointment, one third of the Board will have been refreshed in 2026 alone. The Teleflex Board is now comprised of nine directors, eight of whom are independent.
Mr. Salmon will also serve on the Growth and Operating Committee. The committee was established earlier this year to support management’s continued execution of Teleflex’s strategic transformation, including ongoing initiatives to strengthen operational execution, identify growth opportunities and enhance accountability across the organization.
About Sean M. Salmon
Mr. Salmon is a proven operating executive with more than 30 years of global business leadership experience across the medical device and pharmaceutical sectors, including cardiac ablation, coronary and peripheral vascular disease, and structural heart disease. His background spans commercial operations, business development, research and development, clinical research, regulatory, quality, finance, medical affairs, reimbursement and supply chain, providing the Board with a broad range of perspectives on operating strategy, portfolio management and growth.
Mr. Salmon spent more than two decades at Medtronic, Inc., where he most recently served as Executive Vice President & President, Cardiovascular Portfolio (2020–2025) and previously as Executive Vice President & Group President, Diabetes (2019–2022), President, Coronary and Structural Heart Business Units (2014–2019), President, Coronary and Renal Denervation Business Units (2011–2014), and General Manager, Coronary and Peripheral Business Units (2007–2011). Since December 2025, he has served as owner of Zamboni Holdings, LLC, providing consulting and advisory services in venture, private equity, investment banking and strategy consulting. Mr. Salmon also serves on the Healthcare at Kellogg Advisory Board. He holds an MBA from the Kellogg School of Management at Northwestern University and a B.S. in Applied Physiology from Boston University.
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
Forward Looking Statements
Certain statements made in this press release, other than statements of historical fact, are forward-looking statements, including statements related to the expected contributions of new members of the Board of Directors and the Company’s corporate governance and strategic priorities. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “potential,” “continue” and similar expressions typically identify forward-looking statements. These statements are based on the Company’s current expectations and are not guarantees of future performance; actual outcomes may differ materially due to a number of factors, including those described in Item 1A, Risk Factors, of the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. The Company expressly disclaims any obligation to update these forward-looking statements except as required by law.
Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836
GRAPHIC
GRAPHIC
Filename: image.jpg · Sequence: 6
Binary file (11034 bytes)
Download image.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
8-K Cover Page
Sep. 08, 2026
Cover [Abstract]
Document Type
8-K
Entity Registrant Name
TELEFLEX INCORPORATED
Document Period End Date
Sep. 08, 2026
Entity Incorporation, State or Country Code
DE
Entity File Number
1-5353
Entity Tax Identification Number
23-1147939
Entity Address, Address Line One
550 E. Swedesford Rd., Suite 400
Entity Address, City or Town
Wayne,
Entity Address, State or Province
PA
Entity Address, Postal Zip Code
19087
City Area Code
(610)
Local Phone Number
225-6800
Title of 12(b) Security
Common Stock, par value $1 per share
Trading Symbol
TFX
Security Exchange Name
NYSE
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Entity Emerging Growth Company
false
Entity Central Index Key
0000096943
Amendment Flag
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration